Nuveen Asset Management LLC Trims Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Nuveen Asset Management LLC lowered its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 22.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 345,667 shares of the medical research company's stock after selling 98,179 shares during the period. Nuveen Asset Management LLC owned about 0.27% of NeoGenomics worth $5,697,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Loomis Sayles & Co. L P increased its stake in shares of NeoGenomics by 48.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,791,792 shares of the medical research company's stock valued at $29,528,000 after buying an additional 584,502 shares during the period. Norges Bank bought a new stake in NeoGenomics in the 4th quarter valued at about $6,273,000. Jennison Associates LLC increased its holdings in shares of NeoGenomics by 18.7% during the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock valued at $24,963,000 after acquiring an additional 238,288 shares in the last quarter. Greenhouse Funds LLLP raised its holdings in NeoGenomics by 5.3% during the fourth quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock worth $77,487,000 after buying an additional 237,491 shares during the last quarter. Finally, Segall Bryant & Hamill LLC lifted its position in NeoGenomics by 11.6% in the 4th quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company's stock valued at $34,836,000 after acquiring an additional 220,415 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors.

NeoGenomics Trading Up 0.1%

Shares of NASDAQ:NEO traded up $0.01 during trading on Wednesday, reaching $7.49. 122,249 shares of the company traded hands, compared to its average volume of 1,167,462. The company has a current ratio of 1.98, a quick ratio of 1.91 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a 52-week low of $6.08 and a 52-week high of $19.12. The business's fifty day moving average is $8.46 and its 200-day moving average is $12.25. The firm has a market capitalization of $963.93 million, a price-to-earnings ratio of -12.17 and a beta of 1.60.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). The firm had revenue of $168.04 million during the quarter, compared to the consensus estimate of $171.38 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. NeoGenomics's revenue was up 7.6% on a year-over-year basis. During the same period last year, the business earned ($0.02) EPS. As a group, analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Insider Buying and Selling at NeoGenomics

In related news, Director Michael Aaron Kelly acquired 5,000 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was acquired at an average cost of $7.60 per share, for a total transaction of $38,000.00. Following the acquisition, the director now owns 5,000 shares of the company's stock, valued at $38,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Warren Stone purchased 5,700 shares of NeoGenomics stock in a transaction that occurred on Monday, May 12th. The shares were bought at an average price of $8.58 per share, for a total transaction of $48,906.00. Following the transaction, the chief operating officer now directly owns 108,280 shares of the company's stock, valued at $929,042.40. This trade represents a 5.56% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 70,600 shares of company stock valued at $550,438 in the last 90 days. Insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

NEO has been the subject of a number of research reports. Bank of America reduced their target price on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Wall Street Zen upgraded shares of NeoGenomics from a "sell" rating to a "hold" rating in a research report on Tuesday, May 13th. Morgan Stanley lowered their target price on shares of NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. Guggenheim initiated coverage on shares of NeoGenomics in a research report on Thursday, May 15th. They set a "neutral" rating on the stock. Finally, Needham & Company LLC cut their target price on shares of NeoGenomics from $18.00 to $8.50 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, NeoGenomics presently has a consensus rating of "Hold" and an average price target of $13.83.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.